TNF and rheumatoid arthritis: Current treatment strategies involve traditional disease-modifying anti-rheumatic drugs and novel biologic agents targeting T cells, B cells, pro-inflammatory cytokines including tumor necrosis factor (TNF) or interleukin (IL)-1, and tyrosine kinase activity both markedly improve the clinical outcomes of RA patients [2, 3].